Long-term treatment of symptomatic heart failure

Details Long-term treatment of symptomatic heart failure Long-term treatment of symptomatic heart failure

A - Human Necessities

61

K

A61K 31/23 (2006.01) A61P 9/06 (2006.01)

Patent

CA 2732071

The main object here is the use of omega-3 polyunsaturated fatty acids (as ethyl esters, hereinafter called "n-3 PUFA") as a medicament, either alone or in combination with other therapeutic agents, for reducing mortality for a cardiovascular cause, in particular arrhythmia or for reducing hospitalization for any cause, in particular a cardiovascular cause and for the daily administration to patients with symptomatic heart failure (HF) for more than 3.5 years.

L'invention concerne l'utilisation d'acides gras oméga-3-polyinsaturés (par exemple des éthyl esters, dénommés ci-après "n-3 PUFA") comme médicament, seuls ou combinés à d'autres agents thérapeutiques, afin de réduire la mortalité liée aux affections cardiovasculaires, en particulier à l'arythmie, ou afin de réduire l'hospitalisation pour une raison quelconque, en particulier pour une affection cardiovasculaire, lequel médicament est destiné à être administré quotidiennement aux patients souffrant d'insuffisance cardiaque symptomatique depuis plus de 3,5 ans.

Affiliated with

Also associated with

Rating

Long-term treatment of symptomatic heart failure does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Long-term treatment of symptomatic heart failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Long-term treatment of symptomatic heart failure will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2066213